Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients: A Cohort Study of Patients Treated Either With Docetaxel and Trastuzumab or Docetaxel, Trastuzumab and Pertuzumab

NCT02642458 is registered in ClinicalTrials.gov with University Hospital Tuebingen as lead sponsor.

NCT NCT02642458
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02642458 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients: A Cohort Study of Patients Treated Either With Docetaxel and Trastuzumab or Docetaxel, Trastuzumab and Pertuzumab
Lead sponsor
University Hospital Tuebingen
Phase
Observational
Overall status
Unknown status
Start date
March 31, 2016
Completion date
July 31, 2020
Enrollment
300 (estimated)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer